Re: Miocinovic et al.: Avoiding Androgen Deprivation Therapy in Men With High-risk Prostate Cancer: the Role of Radical Prostatectomy as Initial Treatment. (Urology 2011;77:946-950)

被引：0
|
作者：
Connolly, Stephen S. [1 ]
Walton, Thomas J. [1 ]
Cathcart, Paul J. [1 ]
Costello, Anthony J. [1 ]
Murphy, Declan G. [1 ,2 ]
机构：
[1] Royal Melbourne Hosp, Dept Urol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Div Canc Surg, Melbourne, Vic, Australia
来源：
UROLOGY | 2011年 / 78卷 / 03期
关键词：
D O I：
10.1016/j.urology.2011.05.039
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：724 / 725
页数：2
相关论文
共 50 条
  • [41] COMPARISON BETWEEN MID-TERM OUTCOMES OF HIGH-DOSE-RATE BRACHYTHERAPY WITH EXTERNALBEAM RADIOTHERAPY COMBINED WITH LONG-TERM ANDROGEN DEPRIVATION THERAPY AND RADICAL PROSTATECTOMY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER.
    Onuma, Hajime
    Kimura, Takahiro
    Tashiro, Kojiro
    Yoshiyama, Yasutoshi
    Kido, Masahito
    Yamamoto, Toshihiro
    Sasaki, Hiroshi
    Miki, Jun
    Koike, Yusuke
    Shimomura, Tatsuya
    Yamada, Hiroki
    Miki, Kenta
    Aoki, Manabu
    Egawa, Shin
    JOURNAL OF UROLOGY, 2017, 197 (04): : E633 - E633
  • [42] The importance of the need for better systemic therapy in the definitive treatment of high-risk prostate cancer regardless of whether the initial treatment modality was external beam radiation, I-125 brachytherapy, or radical prostatectomy.
    Ciezki, Jay P.
    Reddy, Chandana A.
    Mian, Omar Y.
    Garcia, Jorge A.
    Klein, Eric A.
    Ulchaker, James
    Angermeier, Kenneth
    Campbell, Steven C.
    Stephenson, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06) : 65 - U5
  • [43] MULTIMODAL TREATMENT FOR HIGH-RISK PROSTATE CANCER WITH HIGH-DOSE INTENSITY-MODULATED RADIATION THERAPY, CONCURRENT INTENSIFIED-DOSE DOCETAXEL AND LONG-TERM ANDROGEN DEPRIVATION THERAPY AFTER RADICAL PROSTATECTOMY AND LYMPHADENECTOMY: RESULTS OF A PROSPECTIVE PHASE II TRIAL.
    Zattoni, Fabio
    Bortolus, Roberto
    Morlacco, Alessandro
    Arcicasa, Mauro
    Matrone, Fabio
    Zattoni, Filiberto
    JOURNAL OF UROLOGY, 2017, 197 (04): : E718 - E719
  • [44] Re: Bo Dai, Sheng Zhang, Fan-Ning Wan, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer : A Phase 2 Randomized Controlled Trial. Eur Urol Oncol 2022;5:519-25
    Montorsi, Francesco
    Barletta, Francesco
    Gandaglia, Giorgio
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (04): : 451 - 451
  • [45] OUTCOMES OF NEOADJUVANT CHEMOHORMONAL THERAPY WITH COMPLETE ANDROGEN BLOCKADE, FOLLOWED BY TREATMENT WITH DOCETAXEL AND ESTRAMUSTINE PHOSPHATE BEFORE RADICAL PROSTATECTOMY IN PATIENTS WITH HIGH-RISK LOCALIZED PROSTATE CANCER: A PROPENSITY-SCORE MATCHING ANALYSIS
    Narita, Shintaro
    Sato, Hiromi
    Kobayashi, Mizuki
    Kikuchi, Akane
    Nara, Taketoshi
    Kanda, Sohei
    Numakura, Kazuyuki
    Koizumi, Atsushi
    Yamamoto, Ryuhei
    Saito, Mitsuru
    Inoue, Takamitsu
    Satoh, Shigeru
    Mitsuzuka, Koji
    Tsuchiya, Norihiko
    Ohyama, Chikara
    Arai, Yoichi
    Nanjo, Hiroshi
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2020, 203 : E1133 - E1133
  • [46] Re: Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-level Data Analysis of 3 Cohorts
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2023, 209 (03): : 635 - 636
  • [47] Apa-RP: Multicenter phase 2 study of apalutamide (Apa) and androgen deprivation therapy (ADT) for the treatment of high-risk localized prostate cancer (HR LPC) following radical prostatectomy (RP)-Results in Black and non-Black patients (pts).
    Hafron, Jason
    Saltzstein, Daniel
    Brown, Gordon
    Belkoff, Laurence
    Aggarwal, Pankaj
    Phillips, Jennifer
    Bhaumik, Amitabha
    McGowan, Tracy
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial
    Mckay, Rana R.
    Xie, Wanling
    Yang, Xiaoyu
    Acosta, Andres
    Rathkopf, Dana
    Laudone, Vincent P.
    Bubley, Glenn J.
    Einstein, David J.
    Chang, Peter
    Wagner, Andrew A.
    Kane, Christopher J.
    Preston, Mark A.
    Kilbridge, Kerry
    Chang, Steven L.
    Choudhury, Atish D.
    Pomerantz, Mark M.
    Trinh, Quoc-Dien
    Kibel, Adam S.
    Taplin, Mary-Ellen
    CANCER, 2024, 130 (09) : 1629 - 1641
  • [49] Re: Par Stattin, Fredrik Sandin, Frederik Birkebaek Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.023 Radical Treatment in Very High-risk Prostate Cancer: Venturing Down a Path Less Travelled
    Santok, Glen Denmer
    Rha, Koon Ho
    EUROPEAN UROLOGY, 2017, 71 (04) : E113 - E114
  • [50] Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
    Narita, Shintaro
    Tsuchiya, Norihiko
    Kumazawa, Teruaki
    Maita, Shinya
    Numakura, Kazuyuki
    Obara, Takashi
    Tsuruta, Hiroshi
    Saito, Mitsuru
    Inoue, Takamitsu
    Horikawa, Yohei
    Satoh, Shigeru
    Nanjyo, Hiroshi
    Habuchi, Tomonori
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
12345